|
1
|
Krüger I, Borowski A, Horst M, de Vivie
ER, Theissen P and Gross-Fengels W: Symptoms, diagnosis, and
therapy of primary sarcomas of the pulmonary artery. Thorac
Cardiovasc Surg. 38:91–95. 1990.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kollár A, Jones RL, Stacchiotti S,
Gelderblom H, Guida M, Grignani G, Steeghs N, Safwat A, Katz D,
Duffaud F, et al: Pazopanib in advanced vascular sarcomas: An EORTC
soft tissue and bone sarcoma group (STBSG) retrospective analysis.
Acta Oncol. 56:88–92. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Schur S, Hamacher R and Brodowicz T:
Pazopanib in primary cardiac angiosarcoma of the right atrium: A
case report. Case Rep Oncol. 9:363–367. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Yoo KH, Kim HS, Lee SJ, Park SH, Kim SJ,
Kim SH, La Choi Y, Shin KH, Cho YJ, Lee J and Rha SY: Efficacy of
pazopanib monotherapy in patients who had been heavily pretreated
for metastatic soft tissue sarcoma: A retrospective case series.
BMC Cancer. 15(154)2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Nakamura Y, Toda K, Miyagawa S, Yoshikawa
Y, Hata H, Domae K, Matsuura R and Sawa Y: Surgical resection and
pazopanib treatment for recurrent cardiac angiosarcoma. Clin
Pathol. 12(2632010X19831261)2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
van der Graaf WT, Blay JY, Chawla SP, Kim
DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP,
Beppu Y, et al: Pazopanib for metastatic soft-tissue sarcoma
(PALETTE): A randomised, double-blind, placebo-controlled phase 3
trial. Lancet. 379:1879–1886. 2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Dewaele B, Floris G, Finalet-Ferreiro J,
Fletcher CD, Coindre JM, Guillou L, Hogendoorn PC, Wozniak A,
Vanspauwen V, Schöffski P, et al: Coactivated platelet-derived
growth factor receptor {alpha} and epidermal growth factor receptor
are potential therapeutic targets in intimal sarcoma. Cancer Res.
70:7304–7314. 2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Sirvent N, Maire G and Pedeutour F:
Genetics of dermatofibrosarcoma protuberans family of tumors: From
ring chromosomes to tyrosine kinase inhibitor treatment. Genes
Chromosomes Cancer. 37:1–19. 2003.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ito Y, Maeda D, Yoshida M, Yoshida A,
Kudo-Asabe Y, Nanjyo H, Izumi C, Yamamoto F, Inoue M, Shibata H, et
al: Cardiac intimal sarcoma with PDGFRβ mutation and
co-amplification of PDGFRα and MDM2: An autopsy case analyzed by
whole-exome sequencing. Virchows Arch. 471:423–428. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Tamborini E, Casieri P, Miselli F,
Orsenigo M, Negri T, Piacenza C, Stacchiotti S, Gronchi A,
Pastorino U, Pierotti MA and Pilotti S: Analysis of potential
receptor tyrosine kinase targets in intimal and mural sarcomas. J
Pathol. 212:227–235. 2007.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Bode-Lesniewska B, Zhao J, Speel EJ,
Biraima AM, Turina M, Komminoth P and Heitz PU: Gains of 12q13-14
and overexpression of mdm2 are frequent findings in intimal
sarcomas of the pulmonary artery. Virchows Arch. 438:57–65.
2001.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Tajima S, Takanashi Y, Takahashi T and
Neyatani H: Intimal sarcoma of the abdominal aorta with
platelet-derived growth factor receptor α overexpression and
amplification in mural invasive cells and pulmonary metastatic
cells but not in intimal spreading cells. Pathol Int. 65:426–431.
2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Tap WD, Jones RL, Van Tine BA, Chmielowski
B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock
G, et al: Olaratumab and doxorubicin versus doxorubicin alone for
treatment of soft-tissue sarcoma: An open-label phase 1b and
randomised phase 2 trial. Lancet. 388:488–497. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yonemori K, Kodaira M, Satoh T, Kudo T,
Takahashi S, Nakano K, Ando Y, Shimokata T, Mori J, Inoue K, et al:
Phase 1 study of olaratumab plus doxorubicin in Japanese patients
with advanced soft-tissue sarcoma. Cancer Sci. 109:3962–3970.
2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Tap WD, Wagner AJ, Schöffski P,
Martin-Broto J, Krarup-Hansen A, Ganjoo KN, Yen CC, Abdul Razak AR,
Spira A, Kawai A, et al: Effect of doxorubicin plus olaratumab vs.
doxorubicin plus placebo on survival in patients with advanced soft
tissue sarcomas: The ANNOUNCE randomized clinical trial. JAMA.
323:1266–1276. 2020.PubMed/NCBI View Article : Google Scholar
|
